The Association Between CBT-I Dose, Sleep Duration, and Fatigue in Breast Cancer Patients

Sponsor

Abramson Cancer Center of the University of Pennsylvania (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05226078

Collaborator

(none)

Enrollment

Location

Arms

Anticipated Duration (Months)

2.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Cancer-related fatigue (CRF) and insomnia are prevalent among cancer patients and have been linked to de-creases in quality of life and poorer overall survivorship. Currently, the mechanisms underlying CRF are not well understood, which has led to treatments that are only moderately effective. In addition, when compared to CBT-I in the general population, the treatment outcomes in CBT-I with cancer patients are subpar and, as such, this study will evaluate whether dose of CBT-I is effective in ameliorating CRF.

Condition or Disease	Intervention/Treatment	Phase
Chronic Insomnia Cancer-related Problem/Condition Cancer-Related Syndrome	Behavioral: Cognitive Behavioral Therapy for Insomnia	N/A

Detailed Description

Subjects will be randomized into one of four groups, four, eight, ten or twelve sessions. Sessions will be con-ducted weekly by Telehealth (via BlueJeans) and will be modified based on the duration of treatment but all will include the following, evaluation and orientation; data acquisition and delivery of sleep restriction therapy & stimulus control instructions; review of sleep hygiene; cognitive therapy [decatastrophization]; managing non-adherence and relapse prevention), and, finally, the final sessions will be largely focused on time-in-bed titration. Treatment will be conducted by a master therapist via a HIPAA compliant video link.

All CBT-I related data will be obtained via dedicated internet websites built with RedCap, where subjects will be asked to complete weekly and monthly questionnaires. One website will be for use by subjects. One website will be for use by the therapist. The patient and therapist website will have a landing page (password entry), a login page, and an activities page (what questionnaires are due when). For an example of such a website, please see our pilot study, https://redcap.med.upenn.edu/surveys/?s=RXLLA7C4KJ (access using password "sleepstudy"). The patient website will contain daily sleep diaries, weekly severity measures of insomnia (ISI), sleepiness (ESS), fatigue (PROMIS 7a & FACIT-F), depression (PHQ-9), anxiety (GAD-7), a medical symptoms checklist.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

70 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Triple (Participant, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

The Association Between CBT-I Dose, Sleep Duration, and Fatigue in Breast Cancer Patients

Anticipated Study Start Date :

Sep 1, 2022

Anticipated Primary Completion Date :

Sep 2, 2023

Anticipated Study Completion Date :

Sep 1, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Four Sessions of CBT-I	Behavioral: Cognitive Behavioral Therapy for Insomnia Cognitive behavioral treatment of insomnia Other Names: CBT-I
Experimental: Eight Sessions of CBT-I	Behavioral: Cognitive Behavioral Therapy for Insomnia Cognitive behavioral treatment of insomnia Other Names: CBT-I
Experimental: Ten Sessions of CBT-I	Behavioral: Cognitive Behavioral Therapy for Insomnia Cognitive behavioral treatment of insomnia Other Names: CBT-I
Experimental: Twelve Sessions of CBT-I	Behavioral: Cognitive Behavioral Therapy for Insomnia Cognitive behavioral treatment of insomnia Other Names: CBT-I

Outcome Measures

Primary Outcome Measures

Recruitment [Baseline to End of Treatment (Up to 12 weeks)]
Proportion of screened eligible subjects who: complete a screener; enroll; and accept randomization.
Adherence [Baseline to End of Treatment (Up to 12 weeks)]
Average adherence to Sleep Restriction Therapy (SRT) and Stimulus Control Therapy (SCT) [overall and by week] as measured by deviations between prescribed and actual times (from sleep diaries), overall and by group.
Treatment Acceptability [End of Treatment]
Average Insomnia Treatment Acceptability Scale (ITAS) scores, overall and by group. Total score for each subscale is the average of the 8 items, with higher scores indicating greater willingness to utilize the treatment.
Retention [Baseline to End of Treatment (Up to 12 weeks)]
Percent of subjects who complete the study, overall and by group.

Eligibility Criteria

Criteria

Ages Eligible for Study:

25 Years to 85 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

The diagnosis of organ-confined BC;
Treatment with RT;
Willingness and ability to provide informed consent;
They endorse problems with both insomnia and CRF, as determined by a score within the significant ranges on the ISI, PROMIS 7a and FACIT-F;
and/or they do not have any significant medical (e.g., OSA; COPD) and/or psychiatric diagnoses (e.g., PTSD).

Exclusion Criteria:

History of untreated obstructive sleep apnea (OSA [defined as an apnea-hypopnea index ≥ 10]) or above threshold scores on the STOP-BANG;
History of narcolepsy;
Night shift work;
Distant metastatic disease at presentation;
Active alcohol and/or drug dependence;
They do not have a diagnosis of BC;
They do not endorse insomnia, CRF and/or do not score within the significant ranges on the ISI, PROMIS 7a and/or the FACIT;
They have a current diagnosis of significant medical and/or psychiatric disorders;
And/or they are not between the ages of 25-85 years.